International Stem Cell (ISCO) Share-based Compensation (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Share-based Compensation of $64000.0 for Q4 2025, down 36.0% year-over-year from $100000.0 in Q4 2024, and up 1.59% quarter-over-quarter from $63000.0 in Q3 2025.
International Stem Cell (ISCO) Share-based Compensation (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Share-based Compensation for 16 consecutive years, with $64000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Share-based Compensation fell 36.0% year-over-year to $64000.0; the TTM figure through Dec 2025 stood at $288000.0 (down 38.2% YoY), while the FY2025 annual figure was $288000.0, down 38.2% from the prior year.
- Share-based Compensation advanced to $64000.0 in Q4 2025 per ISCO's latest filing, from $63000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $234000.0 in Q1 2021 and bottomed at $61000.0 in Q2 2025.
- Historically, Share-based Compensation has averaged $113050.0 across 5 years, with a median of $108500.0 in 2022.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 61.11% — and 2024, when it advanced 26.85%.
- International Stem Cell's Share-based Compensation stood at $120000.0 in 2021, then slipped by 9.17% to $109000.0 in 2022, then rose by 19.27% to $130000.0 in 2023, then retreated by 23.08% to $100000.0 in 2024, then tumbled by 36.0% to $64000.0 in 2025.
- Business Quant data shows ISCO's Share-based Compensation at $64000.0 in Q4 2025, $63000.0 in Q3 2025, and $61000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 81,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 81,000.00 |
| Jun 30, 2026 | 81,000.00 |
| Dec 31, 2025 | 64,000.00 |
| Dec 31, 2025 | 64,000.00 |
| Sep 30, 2025 | 63,000.00 |
| Sep 30, 2025 | 63,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 129,000.00 |
| Jun 30, 2024 | 129,000.00 |
| Mar 31, 2024 | 137,000.00 |
| Mar 31, 2024 | 137,000.00 |
| Dec 31, 2023 | 130,000.00 |
| Dec 31, 2023 | 130,000.00 |